New Indication

The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on the results of the JAVELIN-Renal 101 study.

Learn more by clicking here.